151 related articles for article (PubMed ID: 19854496)
1. Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein.
Scoles DR; Xu X; Wang H; Tran H; Taylor-Harding B; Li A; Karlan BY
Gynecol Oncol; 2010 Jan; 116(1):109-16. PubMed ID: 19854496
[TBL] [Abstract][Full Text] [Related]
2. An agonist of liver X receptor slows valvular disease in a hypercholesterolemia mouse model.
Wang H; Goland S; Burton K; Czer LS; Schwarz ER; Trento A
J Heart Valve Dis; 2010 Sep; 19(5):653-64. PubMed ID: 21053746
[TBL] [Abstract][Full Text] [Related]
3. LXR agonists and ABCG1-dependent cholesterol efflux in MCF-7 breast cancer cells: relation to proliferation and apoptosis.
El Roz A; Bard JM; Huvelin JM; Nazih H
Anticancer Res; 2012 Jul; 32(7):3007-13. PubMed ID: 22753765
[TBL] [Abstract][Full Text] [Related]
4. Oxidized LDL downregulates ATP-binding cassette transporter-1 in human vascular endothelial cells via inhibiting liver X receptor (LXR).
Zhu Y; Liao H; Xie X; Yuan Y; Lee TS; Wang N; Wang X; Shyy JY; Stemerman MB
Cardiovasc Res; 2005 Dec; 68(3):425-32. PubMed ID: 16099444
[TBL] [Abstract][Full Text] [Related]
5. Modified low density lipoprotein stimulates complement C3 expression and secretion via liver X receptor and Toll-like receptor 4 activation in human macrophages.
Mogilenko DA; Kudriavtsev IV; Trulioff AS; Shavva VS; Dizhe EB; Missyul BV; Zhakhov AV; Ischenko AM; Perevozchikov AP; Orlov SV
J Biol Chem; 2012 Feb; 287(8):5954-68. PubMed ID: 22194611
[TBL] [Abstract][Full Text] [Related]
6. Modified low density lipoproteins decrease the activity and expression of lysosomal acid lipase in human endothelial and smooth muscle cells.
Heltianu C; Robciuc A; Botez G; Musina C; Stancu C; Sima AV; Simionescu M
Cell Biochem Biophys; 2011 Sep; 61(1):209-16. PubMed ID: 21499898
[TBL] [Abstract][Full Text] [Related]
7. T0901317 inhibits cisplatin-induced apoptosis in ovarian cancer cells [corrected].
Miller DH; Fischer AK; Chu KF; Burr R; Hillenmeyer S; Brard L; Brodsky AS
Int J Gynecol Cancer; 2011 Nov; 21(8):1350-6. PubMed ID: 21921802
[TBL] [Abstract][Full Text] [Related]
8. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
Taylor-Harding B; Orsulic S; Karlan BY; Li AJ
Gynecol Oncol; 2010 Dec; 119(3):549-56. PubMed ID: 20837358
[TBL] [Abstract][Full Text] [Related]
9. Functional evidence for anti-oxidant action of fluvastatin on low-density lipoprotein using isolated macrophages and aorta.
Kagota S; Yamaguchi Y; Nakamura K; Kunitomo M
Clin Exp Pharmacol Physiol; 2000; 27(5-6):401-5. PubMed ID: 10831243
[TBL] [Abstract][Full Text] [Related]
10. Oxidized LDL Downregulates ABCA1 Expression via MEK/ERK/LXR Pathway in INS-1 Cells.
Lyu J; Fukunaga K; Imachi H; Sato S; Kobayashi T; Saheki T; Ibata T; Yoshimura T; Iwama H; Murao K
Nutrients; 2021 Aug; 13(9):. PubMed ID: 34578896
[TBL] [Abstract][Full Text] [Related]
11. ABCA1 upregulating apolipoproein M expression mediates via the RXR/LXR pathway in HepG2 cells.
Di D; Wang Z; Liu Y; Luo G; Shi Y; Berggren-Söderlund M; Nilsson-Ehle P; Zhang X; Xu N
Biochem Biophys Res Commun; 2012 Apr; 421(1):152-6. PubMed ID: 22516753
[TBL] [Abstract][Full Text] [Related]
12. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
[TBL] [Abstract][Full Text] [Related]
13. TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells.
Zhu C; Di D; Zhang X; Luo G; Wang Z; Wei J; Shi Y; Berggren-Söderlund M; Nilsson-Ehle P; Xu N
Lipids Health Dis; 2011 Nov; 10():199. PubMed ID: 22054074
[TBL] [Abstract][Full Text] [Related]
14. LXRα Regulates oxLDL-Induced Trained Immunity in Macrophages.
Findeisen HM; Voges VC; Braun LC; Sonnenberg J; Schwarz D; Körner H; Reinecke H; Sohrabi Y
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682840
[TBL] [Abstract][Full Text] [Related]
15. Fluvastatin prevents oxidized low-density lipoprotein-induced injury of renal tubular epithelial cells by inhibiting the phosphatidylinositol 3-kinase/Akt-signaling pathway.
Chu G; Jia R; Yang D
J Nephrol; 2006; 19(3):286-95. PubMed ID: 16874687
[TBL] [Abstract][Full Text] [Related]
16. [Study of the clinical significance of ETAR mRNA expression in high-grade serous ovarian cancer and the inhibitory effect of ETAR derived fusion polypeptide on cancer progression].
Zhang YL; Xia XK; Zhang M
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):930-938. PubMed ID: 38123199
[No Abstract] [Full Text] [Related]
17. PDCD1 strengthens the sensitivity of ovarian cancer to cisplatin chemotherapy by promoting apoptosis.
Li Q; Gao JF; Qi BL
J BUON; 2017; 22(3):746-756. PubMed ID: 28730785
[TBL] [Abstract][Full Text] [Related]
18. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
[TBL] [Abstract][Full Text] [Related]
19. A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor.
Blaschke F; Takata Y; Caglayan E; Collins A; Tontonoz P; Hsueh WA; Tangirala RK
Circ Res; 2006 Dec; 99(12):e88-99. PubMed ID: 17110595
[TBL] [Abstract][Full Text] [Related]
20. Treatment with TO901317, a synthetic liver X receptor agonist, reduces brain damage and attenuates neuroinflammation in experimental intracerebral hemorrhage.
Wu CH; Chen CC; Lai CY; Hung TH; Lin CC; Chao M; Chen SF
J Neuroinflammation; 2016 Mar; 13(1):62. PubMed ID: 26968836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
